title: A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV).
abstract: OBJECTIVE
  The study was performed to investigate the anti-tumor effect, survival rate, and toxicity of intermittent intrahepatic infusion chemotherapy with carboplatin suspended in lipiodol.
  
  
  METHODS
  We conducted a randomized controlled study containing either doxorubicin or carboplatin in 65 patients with advanced hepatocellular carcinoma.
  
  
  RESULTS
  The results observed in the carboplatin- and doxorubicin-lipiodol groups included: response rates, 29.0 and 20.6% respectively, 1-year survival rates of, 60.4% and 40.4%, respectively, and the difference achieved statistical significance (p=0.025). The median survival of 31 patients who received carboplatin emulsified with lipiodol was 16.9 months, 34 patients who received doxorubicin was 12.1 months. The difference achieved statistical significance.
  
  
  CONCLUSIONS
  Compared with doxorubicin, carboplatin caused neither cardiotoxicity nor nephrotoxicity, and side effects of nausea and vomiting were less severe. Therefore, carboplatin is effective and preferable for repeated intrahepatic arterial administration to treat advanced hepatocellular carcinoma over a relatively long period.
authors.affiliation: Gastroenterology Center, Tokeidai Hospital, Sapporo, Japan. hisahomma@tokeidaihosp.or.jp
authors.forename: Hisato
authors.initials: H
authors.lastname: Homma
authors.forename: Shinichi
authors.initials: S
authors.lastname: Mezawa
authors.forename: Tadashi
authors.initials: T
authors.lastname: Doi
authors.forename: Koji
authors.initials: K
authors.lastname: Miyanishi
authors.forename: Kohichi
authors.initials: K
authors.lastname: Takada
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kukitsu
authors.forename: Takaomi
authors.initials: T
authors.lastname: Oku
authors.forename: Eiichi
authors.initials: E
authors.lastname: Masuko
authors.forename: Shuuichi
authors.initials: S
authors.lastname: Nojiri
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004655:Emulsions; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; D004655:Emulsions; D007459:Iodized Oil; D004317:Doxorubicin; D016190:Carboplatin